As it has now become the expected level of stock analysis from the Motley Crew, The key factors that negate its observations are either over-looked or never understood by the Crew. Navidea has deliberately taken a loan guarantee from 2 sources which allow Navidea nearly $50 million for operating expenses for the next 3 years if needed. Of course, that much or for that long will not be needed as Lymphoseek is now running its own crew of 12 sales people to correct the Cardinal sales neglect of the past year. The first expected gains will be seen in the early August report.
The FDA granted Lymphoseek Fast Track status to insure quicker movement through the FDA approval process because the FDA saw LS as a serious improvement over current technology.
Following, the FDA determined that Lymphoseek qualified for a special status of its FDA filing fees which resulted in the return to Navidea of over $1 million dollars in filing fees. The FDA inspects all the companies facilities including manufacturing before a drug is approved. So if you are impling that Navidea is not a completely above board company then you are also implying that the FDA is in a conspiracy with Navidea to deceive investors. You really know how to stretch for a fantasy, mrw, when all else fails. Your boss must be so proud...lol
In September 2014, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization for Lymphoseek for use in the EU in imaging and intraoperative detection of sentinel lymph nodes draining a primary tumor in adult patients with breast cancer, melanoma, or localized squamous cell carcinoma of the oral cavity.
In September 2014, Navidea received a notice of award for a Fast Track Small Business Innovation Research (SBIR) grant providing for up to $1.67 million from the National Cancer Institute National Institutes of Health (NIH), to fund evaluation of Lymphoseek in women with cervical cancer.
We are seeing MT move the stock today and there is more MT news on the way but there is also LS news on the way..... the results of the August revenue report are not in doubt. The new in-house sales team has started its grand campaign adding revenue over Cardinal and this is not a broad campaign at this stage but a richly targeted approach. The team is headed for the largest most concentrated cancer service centers in the US. It is there that their efforts will payoff immediately. The follow on quarters (full staff - full quarter) will move the team to all oncologists and surgeons in the US. As with the previous sales, LS will expand the 80% repeat ordering rate. Once LS is used by dedicated medical staffs, it is overwhelmingly adopted for ongoing future orders.
MT moving towards excellence. This is the opportunity to show proof of concept and big pharma will be watching closely. There will be many other product opportunities/partnerships for MT technology. MT stock will also show market opportunities as it goes for a partial IPO later. All NAVB stockholders will receive a number of MT shares in the spin-off IPO based on the number of NAVB shares they own.
I told you to buy when the big short hijacked the Crede deal and took the pps to the low $1's but you were too busy bashing to take advantage and the stock quickly went over $2. Then the stock went to the $1.50's and then back to the $2's. Then went back to the $1.40's and back to the $2's again. A few quicker moves happened for about 25 cents and some a little bigger. Then big short pushed it under a dollar and I told you to buy but you bashed instead and it went again over $2. Then the stock moved around above $1.50 and for a little over a month the stock moved down to the 1.20's and now back in the $1.40's and eventually it is heading for the $1.50's. You missed all this action because you have your head stuck in bash mode and I expect that to continue as NAVB makes its move above $2 again with help from Goldman Sachs who likely anticipates bigger revenue coming from the new in-house sales team and it is to report in August.
The Dow Jones had headed down for several days (300 points) and at the very same time NAVB moved up 15%. You sold at 1.25 for the 10th time this year. I understand you are bad at timing...lol
"this will continue unfortunately"
but its not unfortunate for longs to have 261K on the BID and little on the ASK. Someone (GS or BS) wants to buy lots of NAVB shares and virtually no one wants to sell at this price.
You don't need to pay attention to just LifeTechCapital. I'd pay more attention to Goldman Sachs who bought over 3 million shares of NAVB recently and might actually be buying more right here and .right now. You can speculate what target price GS has for this stock but it is worth noting that GS bought those shares it holds at around $1.65. A double is about right for GS style of investing in small caps.
could be adding shares here and that is the reason for the move up or BS is working his way out of a disaster of a short position. Either way the prospects for the August revenue report are not in doubt. The new in-house sales team has started its grand campaign adding revenue over Cardinal and this is not a broad campaign at this stage but a richly targeted approach. The team is headed for the largest most concentrated cancer service centers in the US. It is there that their efforts will payoff immediately. The follow on quarters (full staff - full quarter) will move the team to all oncologists and surgeons in the US. As with the previous sales, LS will expand the 80% repeat ordering rate. Once LS is used by dedicated medical staffs, it is overwhelmingly adopted for ongoing future orders.
Goldman Sachs usually makes stock upgrades and then as routine gets them reported on one or more investment news services. The exception is when GS actually wants to own a company's stock. GS then just buys the stock with no announcement as that would look like touting. So what do we have? GS recently buys over 3 million shares of NAVB. If GS had only been upgrading NAVB and giving its target price as analysts normally do...what would be the GS target price for this stock? Little big short must be spinning wildly in his trading chair with even more to worry about now that GS is in direct opposition to the BS short position.
Enjoy the price BS is offering. Unfortunately, the stock offered at $1.25 was unavailable to retail traders. It was one of those BS to BS trades (trade time 4:05pm and 4:14pm) past end of day trading which we have seen from BS over and over. BS trades with himself so you can post that it closed at $1.25 and is everyone here real scared...lol
Big short covered about a quarter of a million short shares in the last short volume report. Everyday BS is playing with the stock on low volume and mostly near the end of the daily session. Today it was 225K shares near the end or half of the daily volume. Will we see in the next short volume report another half to full million short shares covered? Only a matter of time before BS is gone or Doom will crush BS as Navidea gains increased revenue every quarter.
There is not the slightest doubt that whatever the new 12 member sales team produces this quarter, it will add to the quarter revenue. It was up 26% last quarter with no new team at work so what higher increase number can we expect this coming quarter report? Every quarter from here should show higher and higher revenue.
As the last minutes tick away, BS makes a move for any day traders waffling here. 25% of the day's volume at the last minute....lol
118K on the Bid and only 12K on the Ask with less than 200K for a day of trading shows how this is not going well for big short. He can't even tread water here with volume so low, he is putting everyone to sleep and still no retail sellers.
"we are all waiting is the stock is in the gutter"
NAVB new investors include Goldman Sachs who recently bought over 3 million shares and bought them around $1.65. Good for longs and a bad omen for the big short. All the bashing you and mrw have been doing over the last few days has not moved the stock down but instead moved it up. Does that mean your boss is now slowly capitulating?
Institutions do not day trade or swing trade when they invest. Goldman Sachs bought almost their entire NAVB position before the end of last quarter. So that would make their cost of entry about $1.65 per share. Goldman has the opportunity to get closer to a company than retail investors. Following their own due diligence has led them to buy a sizable stake in this company.
It is going higher (a lot higher) but the timing depends on how long BS can sit wondering what to do with his losing short. Generally an idiot waits until its past too late and then acts in a rush of panic. Panic will be sweet if you're long NAVB (that's what Goldman Sachs thinks).
"dead money for another 6 months or"
So you're thinking BS is dumb enough to not cover now and wait until the new team brings in better revenue and the pps is soaring higher (with Goldman and others buying more stock). As I said, the dumbest short fund on the Street.....